XBiotech Inc.
XBIT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.06 | 0.20 | -0.04 | -0.31 |
| FCF Yield | -26.82% | -15.74% | -14.42% | 19.71% |
| EV / EBITDA | 1.17 | 3.49 | 1.58 | -4.34 |
| Quality | ||||
| ROIC | -21.85% | -17.01% | -13.96% | -6.31% |
| Gross Margin | 0.00% | 0.00% | 83.77% | 68.36% |
| Cash Conversion Ratio | 0.80 | 0.76 | 0.45 | -3.99 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -55.00% | 2,639,625.25% |
| Free Cash Flow Growth | -69.05% | -23.87% | -123.38% | 195.71% |
| Safety | ||||
| Net Debt / EBITDA | 4.51 | 8.86 | 4.93 | 10.56 |
| Interest Coverage | -52.63 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -1,189.54 | 47.90 |